[1]Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, Yang L, Jiao Z, Luo J, Zi Y, Sun G, Zhang J, Shi Y, Liu J (2018) BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol 151(1):145-152. https://doi.10.1016/j.ygyno.2018.07.024. Epub 2018 Aug 2.
[2]Feng H, Gu ZY, Li Q, Liu QH, Yang XY, Zhang JJ (2019) Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res 12(1):35.https://doi.10.1186/s13048-019-0508-2.
[3]Pignata S, Scambia G, Bologna A, Signoriello S, Vergote IB, Wagner U, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Piccirillo MC, Gallo C, Perrone F (2017) Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol 35(29):3347-3353. https://doi.10.1200/JCO.2017.73.4293. Epub 2017 Aug 21.
[4]Harris FR, Zhang P, Yang L, Hou X, Leventakos K, Weroha SJ, Vasmatzis G, Kovtun IV (2019) Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Mol Oncol 13(2):132-152. https://doi.10.1002/1878-0261.12414. Epub 2018 Dec 21.
[5]European Colorectal Cancer Screening Guidelines Working Group, von Karsa, L., Patnick, J., Segnan, N., Atkin, W., Halloran, S., Lansdorp-Vogelaar, I., Malila, N., Minozzi, S., Moss, S., Quirke, P., Steele, R. J., Vieth, M., Aabakken, L., Altenhofen, L., Ancelle-Park, R., Antoljak, N., Anttila, A., Armaroli, P., Arrossi, S., … Valori, R. (2013) European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 45(1):51–59. https://doi.org/10.1055/s-0032-1325997
[6]Peterson, J. F., Aggarwal, N., Smith, C. A., Gollin, S. M., Surti, U., Rajkovic, A., Swerdlow, S. H., & Yatsenko, S. A. (2015) Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?. Oncotarget 6(22):18845–18862. https://doi.org/10.18632/oncotarget.4586
[7]Cooper C. S. (2001) Applications of microarray technology in breast cancer research. Breast cancer research 3(3):158–175. https://doi.org/10.1186/bcr291
[8]Ahlfors, H., Anyanwu, N., Pakanavicius, E., Dinischiotu, N., Lana-Elola, E., Watson-Scales, S., Tosh, J., Wiseman, F., Briscoe, J., Page, K., Fisher, E., & Tybulewicz, V. (2019) Gene expression dysregulation domains are not a specific feature of Down syndrome. Nature communications 10(1):2489. https://doi.org/10.1038/s41467-019-10129-9
[9]Wang, Z., Monteiro, C. D., Jagodnik, K. M., Fernandez, N. F., Gundersen, G. W., Rouillard, A. D., Jenkins, S. L., Feldmann, A. S., Hu, K. S., McDermott, M. G., Duan, Q., Clark, N. R., Jones, M. R., Kou, Y., Goff, T., Woodland, H., Amaral, F., Szeto, G. L., Fuchs, O., Schüssler-Fiorenza Rose, S. M., … Ma'ayan, A. (2016) Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd. Nature communications 7:12846. https://doi.org/10.1038/ncomms12846
[10]Forés-Martos, J., Catalá-López, F., Sánchez-Valle, J., Ibáñez, K., Tejero, H., Palma-Gudiel, H., Climent, J., Pancaldi, V., Fañanás, L., Arango, C., Parellada, M., Baudot, A., Vogt, D., Rubenstein, J. L., Valencia, A., & Tabarés-Seisdedos, R. (2019) Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. Molecular autism 10:17. https://doi.org/10.1186/s13229-019-0262-8
[11]Xu, Z., Zhang, Q., Luh, F., Jin, B., & Liu, X. (2019) Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer. Oncology letters 17(2):1865–1876. https://doi.org/10.3892/ol.2018.9762
[12]Bonome, T., Levine, D. A., Shih, J., Randonovich, M., Pise-Masison, C. A., Bogomolniy, F., Ozbun, L., Brady, J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer research 68(13):5478–5486. https://doi.org/10.1158/0008-5472.CAN-07-6595
[13]Tung, C. S., Mok, S. C., Tsang, Y. T., Zu, Z., Song, H., Liu, J., Deavers, M. T., Malpica, A., Wolf, J. K., Lu, K. H., Gershenson, D. M., & Wong, K. K. (2009) PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology 22(9):1243–1250. https://doi.org/10.1038/modpathol.2009.92
[14]Yeung, T. L., Leung, C. S., Wong, K. K., Samimi, G., Thompson, M. S., Liu, J., Zaid, T. M., Ghosh, S., Birrer, M. J., & Mok, S. C. (2013) TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer research 73(16): 5016–5028. https://doi.org/10.1158/0008-5472.CAN-13-0023
[15]Hendrix, N. D., Wu, R., Kuick, R., Schwartz, D. R., Fearon, E. R., & Cho, K. R. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer research 66(3):1354–1362. https://doi.org/10.1158/0008-5472.CAN-05-3694
[16]Noh, K., Mangala, L. S., Han, H. D., Zhang, N., Pradeep, S., Wu, S. Y., Ma, S., Mora, E., Rupaimoole, R., Jiang, D., Wen, Y., Shahzad, M., Lyons, Y., Cho, M., Hu, W., Nagaraja, A. S., Haemmerle, M., Mak, C., Chen, X., Gharpure, K. M., … Sood, A. K. (2017) Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell reports 21(10):2785–2795. https://doi.org/10.1016/j.celrep.2017.11.020
[17]Doll, S., Freitas, F. P., Shah, R., Aldrovandi, M., da Silva, M. C., Ingold, I., Goya Grocin, A., Xavier da Silva, T. N., Panzilius, E., Scheel, C. H., Mourão, A., Buday, K., Sato, M., Wanninger, J., Vignane, T., Mohana, V., Rehberg, M., Flatley, A., Schepers, A., Kurz, A., … Conrad, M. (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575(7784):693–698. https://doi.org/10.1038/s41586-019-1707-0
[18]Sharma, M., & Anirudh, C. R. (2019) In silico characterization of residues essential for substrate binding of human cystine transporter, xCT. Journal of molecular modeling 25(11):336. https://doi.org/10.1007/s00894-019-4233-y
[19]Lang, X., Green, M. D., Wang, W., Yu, J., Choi, J. E., Jiang, L., Liao, P., Zhou, J., Zhang, Q., Dow, A., Saripalli, A. L., Kryczek, I., Wei, S., Szeliga, W., Vatan, L., Stone, E. M., Georgiou, G., Cieslik, M., Wahl, D. R., Morgan, M. A., … Zou, W. (2019) Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer discovery 9(12):1673–1685. https://doi.org/10.1158/2159-8290.CD-19-0338
[20]Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H. J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C., Decker, A. R., Sastra, S. A., Palermo, C. F., Andrade, L. R., Sajjakulnukit, P., Zhang, L., Tolstyka, Z. P., Hirschhorn, T., Lamb, C., Liu, T., … Olive, K. P. (2020) Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science (New York, N.Y.) 368(6486):85–89. https://doi.org/10.1126/science.aaw9872
[21]Jiang, L., Kon, N., Li, T., Wang, S. J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520(7545):57–62. https://doi.org/10.1038/nature14344
[22]Martin, L., & Gardner, L. B. (2015) Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11. Oncogene 34(32):4211–4218. https://doi.org/10.1038/onc.2014.352
[23]Yang, Q., Li, K., Huang, X., Zhao, C., Mei, Y., Li, X., Jiao, L., & Yang, H. (2020) lncRNA SLC7A11-AS1 Promotes Chemoresistance by Blocking SCFβ-TRCP-Mediated Degradation of NRF2 in Pancreatic Cancer. Molecular therapy. Nucleic acids 19:974–985. https://doi.org/10.1016/j.omtn.2019.11.035
[24]Wang, S. F., Chen, M. S., Chou, Y. C., Ueng, Y. F., Yin, P. H., Yeh, T. S., & Lee, H. C. (2016) Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget 7(45):74132–74151. https://doi.org/10.18632/oncotarget.12356
[25]Liu, Y., Fan, X., Zhao, Z., & Shan, X. (2020) LncRNA SLC7A11-AS1 Contributes to Lung Cancer Progression Through Facilitating TRAIP Expression by Inhibiting miR-4775. OncoTargets and therapy 13:6295–6302. https://doi.org/10.2147/OTT.S253082
[26]Li, F., Zhao, X., Sun, R., Ou, J., Huang, J., Yang, N., Xu, T., Li, J., He, X., Li, C., Yang, M., & Zhang, Q. (2020) EGFR-rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway-suppressed ROS. Journal of extracellular vesicles 10(1):e12003. https://doi.org/10.1002/jev2.12003
[27]Oddone, N., Boury, F., Garcion, E., Grabrucker, A. M., Martinez, M. C., Da Ros, F., Janaszewska, A., Forni, F., Vandelli, M. A., Tosi, G., Ruozi, B., & Duskey, J. T. (2020) Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Frontiers in pharmacology 11:574. https://doi.org/10.3389/fphar.2020.00574
[28]Wu, Y., Yu, C., Luo, M., Cen, C., Qiu, J., Zhang, S., & Hu, K. (2020) Ferroptosis in Cancer Treatment: Another Way to Rome. Frontiers in oncology 10:571127. https://doi.org/10.3389/fonc.2020.571127
[29]Liu, P., Feng, Y., Li, H., Chen, X., Wang, G., Xu, S., Li, Y., & Zhao, L. (2020) Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cellular & molecular biology letters 25:10. https://doi.org/10.1186/s11658-020-00205-0